These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 15297399

  • 1. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
    Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K.
    Clin Cancer Res; 2004 Aug 01; 10(15):4991-7. PubMed ID: 15297399
    [Abstract] [Full Text] [Related]

  • 2. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K.
    Cancer Res; 2004 May 15; 64(10):3645-52. PubMed ID: 15150124
    [Abstract] [Full Text] [Related]

  • 3. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K.
    Blood; 2005 Feb 15; 105(4):1768-76. PubMed ID: 15514006
    [Abstract] [Full Text] [Related]

  • 4. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A.
    Leuk Res; 2008 Sep 15; 32(9):1382-92. PubMed ID: 18394702
    [Abstract] [Full Text] [Related]

  • 5. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K.
    Cancer Res; 2004 Apr 01; 64(7):2580-9. PubMed ID: 15059915
    [Abstract] [Full Text] [Related]

  • 6. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q, Nishiuchi R, Kitamura T, Kersey JH.
    Leukemia; 2005 Sep 01; 19(9):1605-12. PubMed ID: 16034464
    [Abstract] [Full Text] [Related]

  • 7. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
    Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S.
    Cancer Res; 2005 Mar 15; 65(6):2422-32. PubMed ID: 15781658
    [Abstract] [Full Text] [Related]

  • 8. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
    Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S.
    Mol Pharmacol; 2005 Apr 15; 67(4):1166-76. PubMed ID: 15625278
    [Abstract] [Full Text] [Related]

  • 9. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
    Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K.
    Mol Cancer Ther; 2003 Oct 15; 2(10):971-84. PubMed ID: 14578462
    [Abstract] [Full Text] [Related]

  • 10. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 11. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K.
    Clin Cancer Res; 2005 Sep 01; 11(17):6382-9. PubMed ID: 16144943
    [Abstract] [Full Text] [Related]

  • 12. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.
    Blood; 2003 Feb 15; 101(4):1494-504. PubMed ID: 12406902
    [Abstract] [Full Text] [Related]

  • 13. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
    Rosato RR, Almenara JA, Maggio SC, Atadja P, Craig R, Vrana J, Dent P, Grant S.
    Mol Cancer Ther; 2005 Nov 15; 4(11):1772-85. PubMed ID: 16275999
    [Abstract] [Full Text] [Related]

  • 14. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T.
    Blood; 2005 Jan 01; 105(1):335-40. PubMed ID: 15345593
    [Abstract] [Full Text] [Related]

  • 15. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 16. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
    Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM.
    Leukemia; 2008 Jan 15; 22(1):147-60. PubMed ID: 17928881
    [Abstract] [Full Text] [Related]

  • 17. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
    Yoshida A, Ookura M, Zokumasu K, Ueda T.
    Biochem Pharmacol; 2014 Jul 01; 90(1):16-24. PubMed ID: 24735609
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

  • 19. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun 01; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 20. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K, Bolck HA, Buchwald M, Spielberg S, Polzer H, Spiekermann K, Bug G, Heinzel T, Böhmer FD, Krämer OH.
    Mol Cancer Ther; 2012 Nov 01; 11(11):2373-83. PubMed ID: 22942377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.